What is an appropriate dosing protocol for a 57-year-old female receiving intramuscular testosterone cypionate (total 70 mg per month) and estradiol cypionate (total 4 mg per month) for menopausal symptoms?

Dosing Protocol for IM Testosterone and Estradiol Cypionate in Menopausal Women

For a 57-year-old woman requiring 70 mg testosterone cypionate and 4 mg estradiol cypionate monthly for menopause symptoms, administer testosterone cypionate 17.5 mg IM weekly and estradiol cypionate 1 mg IM weekly, both injected on the same day for convenience and to maintain stable hormone levels.

Testosterone Cypionate Dosing

The FDA-approved dosing for testosterone cypionate allows for flexible administration schedules 1. While the guidelines primarily address male hypogonadism, they emphasize that smaller doses with more frequent injections maintain circulating testosterone levels in the normal range better than larger, less frequent doses 2.

Specific Testosterone Protocol:

• Dose: 17.5 mg IM weekly (totaling 70 mg/month)
• Site: Deep gluteal muscle or anterolateral thigh
• Frequency: Every 7 days, same day each week

Rationale: Weekly dosing prevents the supraphysiologic peaks and subtherapeutic troughs seen with every-2-week or monthly injections 3. This is particularly important in women, where testosterone injections are associated with greater cardiovascular risk when levels fluctuate excessively 3. Recent evidence specifically warns against high-dose injectable estrogens causing supraphysiologic levels 4, and the same principle applies to testosterone in postmenopausal women 5.

Estradiol Cypionate Dosing

The FDA label for estradiol cypionate indicates typical dosing of 1-5 mg every 3-4 weeks for menopausal symptoms 6. However, this creates significant hormone fluctuation.

Specific Estradiol Protocol:

• Dose: 1 mg IM weekly (totaling 4 mg/month)
• Site: Deep gluteal muscle or anterolateral thigh (can be same injection site as testosterone)
• Frequency: Every 7 days, administered same day as testosterone

Rationale: The FDA label notes that a single 5 mg injection produces estrogenic effects lasting 3-4 weeks with relief of vasomotor symptoms for 1-8 weeks (average 5 weeks) 6. Dividing the monthly dose into weekly injections of 1 mg provides more stable estradiol levels. Physiological E2 levels in postmenopausal women can generally be reached with approximately 2 mg oral estradiol or 100 µg transdermal 7, making 4 mg monthly via injection reasonable when accounting for depot kinetics.

Monitoring Protocol

Initial Assessment (Before Starting):

• Baseline testosterone and estradiol levels
• Lipid panel, liver function tests
• Mammogram (if not current)
• Endometrial assessment if uterus present
• Blood pressure, weight, BMI
• Hematocrit

Follow-up Schedule:

At 3-6 weeks after initiation:

• Measure testosterone and estradiol levels mid-cycle (3-4 days after injection) 8, 9
• Target testosterone in premenopausal physiologic range (approximately 15-70 ng/dL total testosterone for women)
• Target estradiol levels should be physiologic for postmenopausal women on HRT (typically 40-100 pg/mL)
• Assess for androgenic side effects (acne, hirsutism, voice changes)
• Evaluate symptom improvement

Every 6 months thereafter:

• Testosterone and estradiol levels
• Lipid panel (testosterone can affect lipid profiles) 10
• Hematocrit (testosterone can increase) 8
• Weight and blood pressure
• Clinical assessment for androgenic excess
• Symptom control evaluation

Annually:

• Mammogram
• Endometrial assessment if uterus present and any abnormal bleeding
• Comprehensive metabolic panel

Critical Safety Considerations

Absolute contraindications:

• Breast cancer (current or history) 8, 9
• Endometrial cancer
• Cardiovascular disease (relative contraindication, use extreme caution)
• Liver disease 11
• Thromboembolic disease

Warning signs requiring immediate evaluation:

• Virilization symptoms (voice deepening, clitoral enlargement)
• Abnormal vaginal bleeding
• Chest pain or shortness of breath
• Severe headaches
• Visual changes

Important Caveats

1. No FDA-approved testosterone preparation exists for women 9, 5. This represents off-label use of male-formulated products at reduced doses.

2. Compounded preparations have inconsistent dosing 11. If using compounded products, verify concentration with each refill.

3. Injectable testosterone and estradiol cause supraphysiologic levels when dosed too high 4, 5. The weekly divided dosing strategy mitigates this risk but requires careful monitoring.

4. Long-term safety data beyond 6 months are lacking for testosterone in postmenopausal women 9, 11, 10. The Endocrine Society recommends against routine testosterone use in women except for specific indications like hypoactive sexual desire disorder 9.

5. If the patient has a uterus, progestogen therapy is mandatory to prevent endometrial hyperplasia 12, 13, 6. This protocol does not include progestogen—ensure it is prescribed separately if needed.

6. Transdermal routes are generally preferred over injections for both hormones due to more stable levels and better safety profiles 12, 13. Consider transitioning to transdermal formulations if available and acceptable to the patient.